A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
Conditions
Locally Advanced Solid Tumor · Metastatic Solid Tumor
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Yale Cancer Center-Yale University, New Haven, Connecticut, United States
START Midwest, Grand Rapids, Michigan, United States
Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
MD Anderson Cancer Center, Houston, Texas, United States
NEXT Oncology, San Antonio, Texas, United States
NEXT Oncology, Fairfax, Virginia, United States
Centre Leon Berard, Lyon, France
Institut de Cancerologie de l'Ouest (ICO)- CRLCC Rene Gauducheau, Saint-Herblain, France
Gustave Roussy Cancer Campus Grand Paris- (Institut de Cancerologie Gustave-Roussy), Villejuif, France
Hospital Universitari Vall d'Hebron, Barcelona, Spain
NEXT Quiron-Barcelona, Barcelona, Spain
START Madrid CIOCC Hospital Universitario HM Sanchinarro, Madrid, Spain
Study leads
Ipsen Medical Director
Study Director
Ipsen